Cellzome vice president Biology Oliver Rausch said that the BioMAP platform will allow them to receive early insight into the human pharmacological and toxicological properties of theeir small molecules, enabling them to develop safer and more effective treatments for inflammation.
Asterand CEO Martyn Coombs said that BioMAP platform is suited for predicting possible human clinical responses of the small molecules Cellzome identifies with its proprietary screening and profiling technologies, Kinobeads and Episphere.